

## Short Communication

### EXPRESSION OF CYTOCHROME P450 AND OTHER BIOTRANSFORMATION GENES IN FETAL AND ADULT HUMAN NASAL MUCOSA

Received May 29, 2005; accepted July 8, 2005

#### ABSTRACT:

Despite recent progress in the identification and characterization of numerous nasal biotransformation enzymes in laboratory animals, the expression of biotransformation genes in human nasal mucosa remains difficult to study. Given the potential role of nasal biotransformation enzymes in the metabolism of airborne chemicals, including fragrance compounds and therapeutic agents, as well as the potential interspecies differences between laboratory animals and humans, it would be highly desirable to identify those biotransformation genes that are expressed in human nasal mucosa. In this study, a global gene expression analysis was performed to compare biotransformation enzymes expressed in human fetal and adult nasal mucosa to those expressed in liver. The

identities of a list of biotransformation genes with apparently nasal mucosa-selective expression were subsequently confirmed by RNA-polymerase chain reaction (PCR) and DNA sequencing of the PCR products. Further quantitative RNA-PCR experiments indicated that, in the fetus, aldehyde dehydrogenase 6 (ALDH6), CYP1B1, CYP2F1, CYP4B1, and UDP glucuronosyltransferase 2A1 are expressed preferentially in the nasal mucosa and that ALDH7, flavin-containing monooxygenase 1, and glutathione *S*-transferase P1 are at least as abundant in the nasal mucosa as in the liver. The nasal mucosal expression of CYP2E1 was also detected. These findings provide a basis for further explorations of the metabolic capacity of the human nasal mucosa for xenobiotic compounds.

Biotransformation of xenobiotic compounds in the nasal mucosa may play important roles in chemical toxicity, drug efficacy, and, possibly, detection of odorants (see Ding and Dahl, 2003, for a recent review). Numerous biotransformation enzymes have been identified in the nasal mucosa in mammals, including cytochrome P450 (P450) monooxygenases, flavin-containing monooxygenases (FMOs), aldehyde dehydrogenases (ALDHs), alcohol dehydrogenase, carboxylesterases, epoxide hydrolases, UDP-glucuronosyltransferase (UGT), glutathione *S*-transferases (GSTs), sulfotransferases, and rhodanese (Ding and Dahl, 2003). However, only a few of these enzymes, such as CYP2A13, have been studied in human nasal mucosa (Ding and Dahl, 2003; Ding and Kaminsky, 2003), primarily because of the lack of sufficient quantities of human nasal tissue samples for *in vitro* studies. A detailed knowledge of biotransformation enzyme expression in human nasal mucosa is critical for our ability to determine the roles of human nasal biotransformation enzymes in drug metabolism, chemical toxicity, and chemoreception.

Recent advances in genomic technologies have made it possible to detect and quantify gene expression using small amounts of RNA samples. In the present study, we first performed a global gene expression analysis, so as to obtain preliminary data on the biotransformation genes expressed in human fetal and adult nasal mucosa. Gene expression in fetal and adult liver was also examined and

compared with that in the nasal tissues, for identification of those genes that are preferentially expressed in the nasal mucosa. The nasal expression of a list of biotransformation genes that were identified by the microarray analysis as "nasal mucosa-predominant" was subsequently confirmed by qualitative RNA-PCR and DNA sequencing. Further quantitative RNA-PCR experiments were performed to determine the relative expression levels of the apparently nasal mucosa-predominant biotransformation genes, in fetal liver and nasal mucosa. Our findings provide a basis for further explorations of the metabolic capacity of the human nasal mucosa for xenobiotic compounds.

#### Materials and Methods

**Total RNA Preparation.** The Institutional Review Boards at the participating institutions approved the study. Human fetal liver and nasal mucosa were provided by the University of Washington Birth Defects Research Laboratory. Adult nasal biopsy samples (from the middle or upper nasal turbinate) were obtained at Shandong University, China; all subjects underwent nasal polypectomy and had normal sense of smell. The postmortem time for the fetal samples was less than 30 min, and the adult nasal biopsy samples were frozen within 30 min of dissection. Total RNA was prepared with use of TRIzol reagent (Invitrogen, Carlsbad, CA). Quality of RNA was assessed by the  $A_{260}/A_{280}$  ratio and by electrophoretic analysis on denaturing gels. Autopsy liver RNA from a 27-year-old male Asian, who died suddenly of unknown causes (postmortem time unknown), was obtained from BD Biosciences Clontech (Palo Alto, CA). The RNA samples were used for RNA-PCR and microarray analysis.

**GeneChip Microarray Analysis.** The Affymetrix GeneChip Instrument System (Affymetrix, Santa Clara, CA) was used to perform global expression analysis at the Wadsworth Center Microarray Core facility. Prior to microarray analysis, RNA samples were further purified with an RNeasy kit from QIAGEN (Valencia, CA). The purified RNA samples were used to prepare double-stranded cDNAs, which in turn were used to synthesize biotin-labeled cRNAs.

This work was supported in part by grants from the National Institutes of Health (ES07462 and CA092596); a Fogarty International Research Collaboration Award (TW01177) from the Fogarty International Center, National Institutes of Health; and a grant from Givaudan Fragrance Research.

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.

doi:10.1124/dmd.105.005769.

**ABBREVIATIONS:** P450, cytochrome P450; PCR, polymerase chain reaction; ALDH, aldehyde dehydrogenase; FMO, flavin-containing monooxygenase; UGT, UDP-glucuronosyltransferase; GST, glutathione *S*-transferase; bp, base pair(s).

TABLE 1  
*Primers used in qualitative RNA-PCR*

Primers were designed according to the sequences in GenBank and are numbered according to the reference sequence associated with the indicated accession number.

Gene	Primers	Sequence (5'-3')	Product Size	Annealing Temperature	Position (5')	Accession No.
			<i>bp</i>	<i>°C</i>		
ALDH6	Sense	agcccagagagccttag	405	58	2274	U07919
	Antisense	tgaagaccgaggctcct			2678	
ALDH7	Sense	aggattgagggttgagg	510	59	2245	U10868
	Antisense	agagagacaggagacggaac			2754	
CYP1B1	Sense	gacatgatggacgcctttat	569	55	1217	U03688
	Antisense	agctgcatcttagaaagttc			1785	
CYP2E1	Sense	actatgggatgggaaacag	353	57	439	NM_000773
	Antisense	ctccttcaccctttcagaca			791	
CYP2F1	Sense	tggggaagagaagcattgag	486	55	465	J02906
	Antisense	cgccaaagagcaggttatgt			950	
CYP4B1	Sense	taaggccctgatgtgtatg	369	57	339	J02871
	Antisense	tggtactggaaggacacaag			707	
FMO1	Sense	gttactcagactttccatccc	579	57	301	M64082
	Antisense	ttatctttcgctccatcaacc			879	
GSTP1	Sense	acgtggcaggaggctcactc	485	57	125	U62589
	Antisense	tactcagggaggccaggaa			609	
UGT2A1	Sense	ttaccacggagtcctc	360	60	1209	AJ006054
	Antisense	gccgttgctcacacaga			1568	

Fragmented cRNAs were hybridized to Affymetrix GeneChips (U95Av2) according to standard protocols established by the manufacturer. The U95Av2 chip contains probe sets for all full-length genes represented in Build 95 of the UniGene database. The GeneChips were washed and then stained with streptavidin-phycoerythrin using a fluidics station, and the hybridization signals were detected with a laser scanner. The data were analyzed using the Affymetrix MicroArray Suite software (version 5.0). Normalized signal intensity values were used for estimating the relative expression levels of a given transcript in differing samples. The "absolute call" (present, marginal, or absent) for the expression of an individual transcript was determined according to statistical analysis of the differences in hybridization intensity between perfect-match probe and mismatch probes for each probe set. RNA quality and labeling efficiency were confirmed by first hybridizing a portion of the labeled cRNA samples to an Affymetrix Test3 chip, prior to hybridization of the U95Av2 Chip.

**Qualitative RNA-PCR.** RNA-PCR was performed in a PE9600 PCR machine (Applied Biosystems, Foster City, CA) with Thermoscript RNase H<sup>-</sup> reverse transcriptase (Invitrogen). First-strand cDNAs were synthesized at 50°C, with the use of 2 µg of total RNA, 2.5 µM oligo(dT)<sub>16</sub> primer, and 5 mM MgCl<sub>2</sub>, in a total volume of 20 µl. Two microliters of the reverse transcription product were added to PCR mixtures, which contained 0.5 µM concentrations each of the two primers, 0.2 mM concentrations each of deoxynucleoside-5'-triphosphates, 2 mM MgCl<sub>2</sub>, 1× PCR buffer A (Promega, Madison, WI), and 2.5 U of *Thermus aquaticus* polymerase, in a total reaction volume of 50 µl. PCRs were performed for 35 cycles with the following conditions: denaturation at 95°C for 30 s, annealing (at the temperature indicated in Table 1) for 30 s, and elongation at 72°C for 45 s. PCR products were analyzed by electrophoresis on agarose gels, purified using the QIAquick Gel Extraction Kit (QIAGEN), and sequenced by the Molecular Genetics Core facility of the Wadsworth Center, to confirm PCR specificity. Negative control reactions (no template) were routinely included, to monitor potential contamination of reagents.

For detection of CYP2E1 in human fetal nasal mucosa, the reverse transcription reaction was carried out using the SuperScript III First-Strand Synthesis System (Invitrogen). PCR amplification was carried out in a LightCycler (Roche Diagnostics, Mannheim, Germany). Each reaction mixture, in a total volume of 10 µl, contained 1 µl of reverse transcription product, 0.8 µl of 25 mM MgCl<sub>2</sub>, a 0.4 µM concentration of each primer, and 1 µl of LightCycler FastStart DNA Master Reaction Mix SYBR Green I (Roche Applied Science, Indianapolis, IN). Gel-purified PCR product was sequenced for confirming the detection of CYP2E1.

**Quantitative PCR.** Real-time PCR analyses were performed in a LightCycler according to the instructions in the LightCycler Kit (Roche Applied

Science). Primers (Table 2) were used at 0.25 µM in a 20-µl reaction volume. Two microliters of the reverse transcription product (diluted with water or used directly) were added per capillary, and 40 PCR cycles were monitored. At the end of the PCR cycles, melting curve analysis was performed by heating to 95°C, followed by cooling to 65°C, and gradual heating to 92°C at 0.2°C/s.

For each primer set, a serial dilution of the reverse transcription products was made, so that amounts equivalent to 0.2 µg (1/10th) to 0.2 ng (1/10,000th) of the initial total RNA used in the reverse transcription step were used to perform quantitative PCR. This procedure was followed to ensure that the amounts of PCR products detected in the experimental groups fell within the linear range of PCR amplification. For all of the biotransformation enzymes studied, an amount of reverse transcription product equivalent to 0.04 µg of RNA, and a final Mg<sup>2+</sup> concentration of 4.0 mM, gave the best results. Therefore, these parameters were applied to each reaction. All reactions were performed in duplicate. To monitor the extent of potential contributions of contaminating genomic DNA templates to the final PCR products, additional control reactions were performed by omitting reverse transcriptase during the reverse transcription step.

## Results

The Affymetrix GeneChip U95Av2 Array contains a comprehensive (although still incomplete) collection of human genes. A manual inspection identified a number of biotransformation genes represented on this chip, including genes for 6 alcohol dehydrogenases, 11 ALDHs, 31 P450s, 2 epoxide hydrolases, 2 carboxylesterases, 6 FMOs, 12 GSTs, 13 oxidases, 17 reductases, 2 rhodanases, 3 sulfatases, 16 sulfotransferases, and 9 UGTs. Initial screening of available human RNA samples identified four that were of suitable quality for gene array analysis (Table 3). Array analysis detected transcripts of many, but not all, of the biotransformation genes in the nasal mucosal RNA preparations, with a generally good agreement between the results from the fetal and the adult nasal mucosa (data not shown). Although the array data are preliminary, since only a single sample was analyzed for each group, a comparison of the signal intensity in liver and nasal mucosa for the biotransformation genes identified eight that are apparently expressed more abundantly in the nasal mucosa than in the liver, in both fetal and adult samples. The signal intensity values as well as the GenBank accession numbers for this subset of genes are shown in Table 3. Notably, the "absolute calls" (*absent*, *marginal*, or *present*), shown in Table 3, were not used as the

TABLE 2

Primers used in quantitative RNA-PCR

Primer pairs for ALDH6, ALDH7, and CYP4B1 were the same as in Table 1. The accession number for  $\beta$ -actin is BC009275.

Primer	Sequence (5'-3')	Size of PCR Product	Annealing Temperature	Position (5')
		bp	°C	
ALDH6F2274	agccagagagcttag	405	67	2274
ALDH6R2678	tgaagaccgaggtcct			2678
ALDH7F2245	aggattgagggattgaggg	510	65	2245
ALDH7R2754	agagagacaggagacggaac			2754
$\beta$ -actinE3F	cctgactgactacctcatg	396	60	1105
$\beta$ -actinE4R	tccttctgcatacctgtcgcca			1500
CYP1B1F1	cccagtcgtcatcagat	221	62	4304
CYP1B1R1	cattctctctccggtaga			4524
CYP2F1F1	gattctacggaatttcggg	266	62	445
CYP2F1R1	tgtcgtacaactcgcc			710
CYP4B1F	taaggccctgatgtgatg	369	60	339
CYP4B1R	tggactggaaggacacaag			707
FMO1F1363	tgtgctactgcaaggc	227	60	1363
FMO1R1589	cttgaatggttcgggtccc			1589
GSTp1F1	agtcttcgccaccatgccc	375	60	1
GSTp1R1	ttcacatagtcaccttgccac			375
UGT2A1F78	ttggccaatggaaggtagtc	208	60	138
UGT2A1R285	ccatgtcgaaacgaagtcct			345

TABLE 3

Gene array analysis of comparative expression of biotransformation genes in adult and fetal human liver and nasal mucosa

RNA samples were from the liver (FL) and nasal mucosa (FN) of a white female fetus at the gestational age of 115 days (#16029), autopsy liver tissue from a 27-year-old Asian male (AL), and nasal mucosa (AN) from pooled biopsy samples from three male Asian subjects (32, 52, and 66 years old, respectively). Only genes with apparently selective expression in the nasal mucosa are shown. The absolute call was *present*, unless indicated otherwise.

Probe Set	Gene	Accession No.	Signal Intensity			
			FN	FL	AN	AL
			<i>arbitrary units</i>			
36686_at	ALDH6	U07919	1050	129 <sup>a</sup>	1490	248 <sup>a</sup>
40685_at	ALDH7	U10868	2640	380 <sup>a</sup>	2800	708 <sup>a</sup>
40071_at	CYP1B1	U03688	1810	163 <sup>a</sup>	4360	270 <sup>a</sup>
859_at	CYP1B1	U03688	1260	98 <sup>a</sup>	3150	95 <sup>a</sup>
1517_at	CYP2F1	J02906	5730 <sup>b</sup>	635 <sup>a</sup>	3070 <sup>a</sup>	1530 <sup>a</sup>
1667_s_at	CYP4B1	J02871	7370	1700 <sup>a</sup>	5120	2850 <sup>a</sup>
31806_at	FMO1	M64082	625	59 <sup>a</sup>	512	99 <sup>a</sup>
33396_at	GSTP1	U12472	19,600	8570	14,500	6020
829_s_at	GSTP1	U21689	26,100	12,000	17,700	5410 <sup>a</sup>
31646_at	UGT2A	AJ006054	2110	58 <sup>a</sup>	1510	171 <sup>a</sup>

<sup>a</sup> Absolute call, *absent*.<sup>b</sup> Absolute call, *marginal*.

criterion for gene selection, partly because many genes with relatively high signal intensity values were called *absent*. The list of identified genes included two ALDHs, three P450s, one FMO, one GST, and one UGT; the latter, UGT2A1, was reported previously to be nasal mucosa-specific (Jedlitschky et al., 1999). CYP2A13, which is known to be predominantly expressed in the nose (Su et al., 2000), is not included in this list, because the CYP2A probe sets on the gene chip could not distinguish among the three known human CYP2A genes, CYP2A6, CYP2A7, and CYP2A13.

The preliminary data obtained with the gene arrays were confirmed by RNA-PCR with RNA samples from adult liver, fetal liver, and fetal nasal mucosa. Adult nasal mucosa RNA samples were not available for these studies. Specificity of the primers used was confirmed by BLAST analysis of the GenBank database, by the electrophoretic detection of a single band of expected size, and by sequence analysis of purified PCR products (results not shown). As shown in Fig. 1, transcripts of each of the eight genes were detected in total RNA preparations from fetal nasal mucosa. For fetal and adult liver, RNA-PCR products from CYP2F1, CYP4B1, and UGT2A1 were barely detected. However, such tissue selectivity was less obvious for the other five genes.

The sequences of the PCR products matched the reference sequences, except for CYP4B1. The sequence of the PCR product amplified from the nasal CYP4B1 mRNA corresponded to the splice variant found in seminal vesicles (Bylund et al., 1999) and lung (Carr et al., 2003a), with a Ser207 insertion. Unlike the "wild-type" human CYP4B1 protein (Zheng et al., 1998), this CYP4B1 splice variant appears to be functional, as indicated by studies on CYP4B1(Ser207)-transgenic mice (Imaoka et al., 2001). However, although a recombinant fusion protein of CYP4B1(Ser-207) with NADPH-cytochrome P450 reductase was functional (Imaoka et al., 2001), in vitro evidence for the function of a natural CYP4B1 enzyme has yet to be obtained (e.g., Carr et al., 2003a). Sequence of the hepatic CYP4B1 PCR products was not determined, because the products were detected at very low abundance (Fig. 1). In addition, the sequence of CYP2F1 PCR product agreed with the one reported by Chen et al. (2002) and Carr et al. (2003b) (GenBank accession number NM\_000774), with respect to the 12-bp segment in exon 5 that was previously found in a different position (Nhamburo et al., 1990), and the dinucleotide differences at positions 468 and 469 of the CYP2F1 cDNA.

We performed quantitative, real-time RNA-PCR to further evaluate the tissue selectivity of the expression of these eight genes in fetal




FIG. 1. Qualitative RNA-PCR analysis of biotransformation gene expression in fetal nasal mucosa and liver and adult liver. RNA-PCR was performed as described under *Materials and Methods*, with primer pairs and annealing temperatures shown in Table 1. PCR products (10  $\mu$ l each), generated from the same RNA samples as those used for microarray analysis (lanes 1–3, for fetal nasal mucosa, fetal liver, and adult liver, respectively), were analyzed on agarose gels and were visualized by staining with ethidium bromide. The identities of the nasal mucosal PCR products were confirmed by sequencing. The positions of selected size markers are indicated. M, a 100-bp molecular weight marker.

liver and nasal mucosa. For most genes, new sets of PCR primers that were suitable for specific amplification in the LightCycler were designed (Table 2). For all primers, specificity was confirmed by melting curve analysis, by the detection of a single band of expected size on agarose gels, and by sequencing of PCR products (results not shown). Freshly prepared RNAs from the liver and nasal mucosa of two fetuses (number 15777, white; number 16005, African American;

both male and at gestational day 91) were used for quantitative analysis. The level of  $\beta$ -actin mRNA was also quantified in each RNA sample, and the results were used to correct for the variability in the actual amounts of RNA added to the reactions. The primers for  $\beta$ -actin amplify a 396-bp product from  $\beta$ -actin cDNA and a 491-bp product from  $\beta$ -actin genomic DNA. The fact that the 491-bp product was not detected in any of the RNA samples analyzed (data not shown) indicates the absence of significant contamination by genomic DNA. In additional control experiments (not shown), in which the reverse transcriptase was omitted during first-strand cDNA synthesis, PCR products derived from contaminating genomic DNA, which contains processed  $\beta$ -actin pseudogenes (Hurteau and Spivack, 2002), were detected in the RNA samples. However, the amounts of genomic DNA-derived  $\beta$ -actin PCR product were less than 0.1% as plentiful as cDNA-derived  $\beta$ -actin PCR product.

The amounts of PCR products for the four RNA samples were all within the linear range of the standard curves (not shown), except in cases where no product was detected. Values obtained from duplicate reactions were consistent, with differences less than 5% of the means in threshold cycle numbers. For the standard curves, Pearson's correlation coefficients from linear regression were always greater than 0.95. As shown in Table 4, the relative mRNA levels were consistent between the two fetuses examined. Intraindividual comparisons of mRNA levels in the two tissue types indicate that ALDH6, CYP1B1, CYP2F1, CYP4B1, and UGT2A1 were expressed at much higher levels in the nasal mucosa than in the liver. On the other hand, FMO1 and GSTP1 appear to be expressed at similar levels in the two tissues. For ALDH7, a relatively large interindividual difference was found, primarily because of differences in the levels of hepatic ALDH7 mRNA; the tissue expression ratios were 10 and 2.9, respectively, with higher levels in the nasal mucosa than in liver.

A comparison of the results in Tables 3 and 4 indicates that some transcripts, such as CYP2F1, which had been classified as *marginal* or *absent* in the gene array analysis (Table 3), were actually expressed in the nasal mucosa (Table 4). The same situation was found for the expression data for CYP2E1; this enzyme was called *absent* in the nasal mucosa, but was detected by qualitative RNA-PCR and DNA sequencing (data not shown). These discrepancies likely reflect the differing specificities and sensitivities of the two techniques.

The fetal nasal mucosa tissue used in this study was known to contain the olfactory region, because the entire middle and superior turbinates had been used for RNA preparation. The adult nasal biop-

TABLE 4

*Relative mRNA levels in fetal nasal mucosa and liver*

Quantitative RNA-PCR was performed as described under *Materials and Methods*, with use of primers and annealing temperatures shown in Table 2. RNA preparations were from liver and nasal mucosa of two fetuses (#15777 and #16005), both at gestational day 91. The relative levels of each transcript in the four samples were determined with standard curves generated using serial dilutions of pooled nasal RNA. Experiments were performed in duplicate, and the results were corrected on the basis of the levels of  $\beta$ -actin mRNA present in each preparation.

Gene	Relative mRNA Level <sup>a</sup>				Ratio, Nasal Mucosa/Liver		
	#15777		#16005		#15777	#16005	Average
	Nasal Mucosa	Liver	Nasal Mucosa	Liver			
	<i>arbitrary units</i>						
ALDH6	5.0	0.27	2.5	0.27	18	9.2	14
ALDH7	1.6	0.16	1.7	0.59	10	2.9	6.4
CYP1B1	1.8	0.10	1.5	0.091	18	16	17
CYP2F1	10	0.20 <sup>b</sup>	11	0.24 <sup>b</sup>	50	46	48
CYP4B1	15	0.09	6.7	0.07	167	96	132
FMO1	1.6	1.8	1.7	2.3	0.9	0.7	0.8
GSTP1	2.6	1.0	2.1	1.1	2.6	1.9	2.2
UGT2A1	12	0.61	7.3	0.41	20	18	19

<sup>a</sup> For comparisons among the four samples for each gene.

<sup>b</sup> No product was detected in one of the two reactions.

sies also likely contained olfactory mucosa since, of the three samples pooled, two were from the superior turbinate, and one was from the upper part of the nasal septum. Similarly dissected tissues have previously been found (Chen et al., 2003) to express olfactory marker protein, a well known marker for the olfactory neuroepithelium (Buiakova et al., 1994). Notably, although the olfactory marker protein gene was not included on this chip, several neuronal transcripts, such as human olfactory receptor OLF3 (OR2F1, accession number U56421), were *present* in the nasal mucosa but *absent* in liver (data not shown), a finding that further supports the presence of olfactory mucosa in the tissue used here.

### Discussion

Little is known about the metabolic capacity of the human nasal mucosa for numerous xenobiotic compounds. The lack of sufficient quantities of human nasal tissue samples has made it very difficult to directly determine the metabolic activity of nasal biotransformation enzymes. The knowledge of the transcripts expressed, and their relative levels in differing nasal mucosal samples, will facilitate future studies to characterize the expression of the corresponding proteins, which is, at present, a more difficult task than studies on RNA expression. Once the expression of a biotransformation gene has been confirmed, we may be able to predict the metabolic capacity of the nasal mucosa based on the results of *in vitro* studies that use heterologously expressed enzymes.

In this study, using a combination of gene array analysis and RNA-PCR, we have identified transcripts for nine biotransformation genes in human nasal mucosa, namely, ALDH6, ALDH7, CYP1B1, CYP2E1, CYP2F1, CYP4B1, FMO1, GSTP1, and UGT2A1. Furthermore, using quantitative RNA-PCR, we have shown that ALDH6, CYP1B1, CYP2F1, CYP4B1, and UGT2A1 are expressed at much higher levels in the nasal mucosa than in the liver of the same fetuses. These findings, combined with previous detection of CYP2A6, CYP2A13, CYP2B6, CYP2C, CYP2J2, CYP3A, NADPH-cytochrome P450 reductase, microsomal epoxide hydrolase, GSTA, GSTP1, and UGT2A1 in human nasal mucosa (Ding and Dahl, 2003; Ding and Kaminsky, 2003), provide strong support for the idea that human fetal as well as adult nasal mucosa plays an active role in the biotransformation of numerous xenobiotic compounds.

The nasal expression of human ALDH6, ALDH7, CYP1B1, CYP2E1, CYP2F1, CYP4B1, and FMO1 had not been reported previously. GSTP1 and UGT2A1 were previously detected in adult human nasal mucosa (Krishna et al., 1995; Jedlitschky et al., 1999), but their fetal expression had not been examined. In human adults, GSTP1 immunoreactivity was detected in the supporting cells in the olfactory mucosa by immunohistochemical analysis (Krishna et al., 1995). UGT2A1 was cloned from a human nasal mucosal cDNA library and was characterized following heterologous expression (Jedlitschky et al., 1999). Expression of UGT2A1 mRNA was not detected in adult human liver or several other tissues by RNA-PCR, implying that this gene is expressed in a tissue-specific fashion. The nasal mucosa specificity was found for UGT2A1 expression in human fetuses in the present study.

It should be noted that, although we have selected the potentially nasal mucosa-predominant transcripts for characterization in this study, those nasal biotransformation genes that are expressed at similar levels in the liver and in the nasal mucosa could also be important for nasal metabolism. To that end, the present microarray analysis detected the expression of many other biotransformation genes, as well as genes in other functional categories, in fetal as well as adult human nasal mucosa. These results, although preliminary, should serve as a valuable reference for future studies on gene expression in

fetal and adult human nasal mucosa. A survey of current literature found several other studies that used gene array methods to identify genes expressed in the human nose. In one study, gene expression was compared between nasal polyp tissues and normal nasal mucosal samples from sphenoid sinuses (Liu et al., 2004). The gene expression profiles in nasal polyps before and after local treatment with fluticasone were compared in another study (Benson et al., 2004). In an earlier study, gene expression profiles in nasal mucosa from patients with allergic rhinitis were determined and compared between patients with nasal polyps and those without (Fritz et al., 2003). In these studies on adult nasal tissues, the expression of many biotransformation genes, including the nine genes identified in the present study, was suggested by the array data, although further confirmation was not carried out. It would be important to examine the impact of nasal diseases, such as rhinitis, on the expression of biotransformation enzymes in differing nasal tissues, since local metabolism of nasally administered drugs could influence efficacy, or could potentially lead to adverse drug reactions.

**Acknowledgments.** We gratefully acknowledge the use of the Molecular Genetics and the Microarray Cores of the Wadsworth Center. We thank Drs. Laurence Kaminsky and Adriana Verschoor for reading the manuscript.

Wadsworth Center,  
New York State Department of Health, and  
School of Public Health,  
State University of New York at Albany,  
Albany, New York (X.Z., Q.-Y.Z., D.L., T.S.,  
Y.W., G.L., J.G., X.D.);  
Qilu Hospital of Shandong University,  
Jinan, Shandong, China (Y.C.); and  
Givaudan Fragrance Research,  
Zurich, Switzerland (B.S.)

XIULING ZHANG  
QING-YU ZHANG  
DAZHI LIU  
TING SU  
YAN WENG  
GUOYU LING  
YING CHEN  
JUN GU  
BORIS SCHILLING  
XINXIN DING

### References

- Benson M, Carlsson L, Adner M, Jernas M, Rudemo M, Sjogren A, Svensson PA, Uddman R, and Cardell LO (2004) Gene profiling reveals increased expression of uteroglobin and other anti-inflammatory genes in glucocorticoid-treated nasal polyps. *J Allergy Clin Immunol* **113**:1137–1143.
- Buiakova OI, Krishna NS, Getchell TV, and Margolis FL (1994) Human and rodent OMP genes: conservation of structural and regulatory motifs and cellular localization. *Genomics* **20**:452–462.
- Bylund J, Finnstrom N, and Oliv EH (1999) Gene expression of a novel cytochrome P450 of the CYP4F subfamily in human seminal vesicles. *Biochem Biophys Res Commun* **261**:169–174.
- Carr BA, Ramakanth S, Dannan GA, and Yost GS (2003a) Characterization of pulmonary CYP4B2, specific catalyst of methyl oxidation of 3-methylindole. *Mol Pharmacol* **63**:1137–1147.
- Carr BA, Wan J, Hines RN, and Yost GS (2003b) Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif. *J Biol Chem* **278**:15473–15483.
- Chen N, Whitehead SE, Caillat AW, Gavitt K, Ispording DR, Kovacevic D, McCreary MB, and Hoffman SMG (2002) Identification and cross-species comparisons of CYP2F subfamily genes in mammals. *Mutat Res* **499**:155–161.
- Chen Y, Liu YQ, Su T, Ren X, Shi L, Liu DZ, Gu J, Zhang QY, and Ding X (2003) Immunoblot analysis and immunohistochemical characterization of CYP2A expression in human olfactory mucosa. *Biochem Pharmacol* **66**:1245–1251.
- Ding X and Dahl AR (2003) Chapter 3: Olfactory mucosa: composition, enzymatic localization and metabolism. In *Handbook of Olfaction and Gustation*, 2nd ed (Doty RL, ed) pp 51–73, Marcel Dekker, New York.
- Ding X and Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. *Annu Rev Pharmacol Toxicol* **43**:149–173.
- Fritz SB, Terrell JE, Conner ER, Kukowska-Latallo JF, and Baker JR (2003) Nasal mucosal gene expression in patients with allergic rhinitis with and without nasal polyps. *J Allergy Clin Immunol* **112**:1057–1063.
- Hurteau GJ and Spivack SD (2002) mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. *Anal Biochem* **307**:304–315.
- Imaoka S, Hayashi K, Hiroi T, Yabusaki Y, Kamataki T, and Funae Y (2001) A transgenic mouse expressing human CYP4B1 in the liver. *Biochem Biophys Res Commun* **284**:757–762.
- Jedlitschky G, Cassidy AJ, Sales M, Pratt N, and Burchell B (1999) Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. *Biochem J* **340**:3–843.

- Krishna NS, Getchell TV, Dhooper N, Awasthi YC, and Getchell ML (1995) Age- and gender-related trends in the expression of glutathione S-transferases in human nasal mucosa. *Ann Otol Rhinol Laryngol* **104**:812–822.
- Liu Z, Kim J, Sypek JP, Wang IM, Horton H, Oppenheim FG, and Bochner BS (2004) Gene expression profiles in human nasal polyp tissues studied by means of DNA microarray. *J Allergy Clin Immunol* **114**:783–790.
- Nhamburo PT, Kimura S, McBride OW, Kozak CA, Gelboin HV, and Gonzalez FJ (1990) The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression and chromosome mapping. *Biochemistry* **29**:5491–5499.
- Su T, Bao ZP, Zhang Q-Y, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. *Cancer Res* **60**:5074–5079.
- Zheng YM, Fisher MB, Yokotani N, Fujii-Kuriyama Y, and Rettie AE (1998) Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1. *Biochemistry* **37**:12847–12851.

---

**Address correspondence to:** Dr. Xinxin Ding, Wadsworth Center, New York State Department of Health, Empire State Plaza, Box 509, Albany, NY 12201-0509. E-mail: xding@wadsworth.org

---